Nephros Inc. (NEPH) Stock Price

NEPHStock

$4.22+5.50%52W

Market Cap$45.83M

P/E41.84x

PEG Ratio—

Div yield—

Beta1.62

NEPH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)5.73%

Price vs S&P 500 (4W)22.95%

VGM Score49.40

P/E Ratio (Annual)41.84x

P/CF (Annual)30.37x

Book Value / Share (Quarterly)$0.99

P/TBV (Annual)5.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)23.48%

Cash Flow / Share (Quarterly)$-0.03

Price vs S&P 500 (YTD)-21.59%

Gross Margin (TTM)59.95%

Net Profit Margin (TTM)4.06%

EPS (TTM)$0.07

10-Day Avg Trading Volume0.04M

EPS Excl Extra (TTM)$0.07

Revenue Growth (5Y)17.03%

EPS (Annual)$0.11

ROI (Annual)11.69%

Gross Margin (Annual)61.87%

Net Profit Margin (5Y Avg)-23.67%

Cash / Share (Quarterly)$0.37

P/E Basic Excl Extra (TTM)64.38x

Revenue Growth QoQ (YoY)6.87%

P/E Normalized (Annual)41.84x

ROA (Last FY)8.75%

Revenue Growth TTM (YoY)23.25%

EBITD / Share (TTM)$0.08

ROE (5Y Avg)-34.69%

Operating Margin (TTM)3.54%

Cash Flow / Share (Annual)$0.15

P/B Ratio4.67x

P/B Ratio (Quarterly)2.96x

Net Income / Employee (Annual)$33,200

EV / Revenue (TTM)2.40x

Net Interest Coverage (TTM)-427.00x

ROA (TTM)5.86%

EPS Growth QoQ (YoY)-75.86%

EV / EBITDA (TTM)54.77x

EPS Incl Extra (Annual)$0.11

Current Ratio (Annual)4.06x

Quick Ratio (Quarterly)2.98x

3-Month Avg Trading Volume0.02M

52-Week Price Return5.50%

EV / Free Cash Flow (Annual)27.94x

P/E Incl Extra (TTM)64.38x

Revenue / Employee (TTM)$531,200

Tangible BV / Share (Quarterly)$0.94

P/S Ratio (Annual)2.66x

Asset Turnover (Annual)1.38x

52-Week High$6.42

Operating Margin (5Y Avg)-15.13%

EPS Excl Extra (Annual)$0.11

CapEx CAGR (5Y)40.63%

Tangible BV CAGR (5Y)-3.04%

26-Week Price Return16.98%

Quick Ratio (Annual)2.82x

13-Week Price Return19.51%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.55x

Enterprise Value$45.95M

Revenue / Share Growth (5Y)12.69%

Asset Turnover (TTM)1.45x

Book Value / Share Growth (5Y)-5.45%

Revenue / Employee (Annual)$521,900

Inventory Turnover (Annual)2.45x

Pretax Margin (Annual)6.42%

Cash / Share (Annual)$0.51

3-Month Return Std Dev72.71%

Gross Margin (5Y Avg)56.99%

Net Income / Employee (TTM)$21,600

ROE (Last FY)11.70%

Net Interest Coverage (Annual)-95.00x

EPS Basic Excl Extra (Annual)$0.11

P/FCF (TTM)30.37x

Receivables Turnover (TTM)6.17x

EV / Free Cash Flow (TTM)21.08x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.07

Receivables Turnover (Annual)8.96x

ROI (TTM)7.65%

P/S Ratio (TTM)2.61x

Pretax Margin (5Y Avg)-14.82%

Revenue / Share (Annual)$1.71

Tangible BV / Share (Annual)$0.91

Forward P/E36.04x

Price vs S&P 500 (52W)-12.81%

P/E Ratio (TTM)64.38x

EPS Growth TTM (YoY)-5.36%

Year-to-Date Return-9.63%

5-Day Price Return-3.92%

EPS Normalized (Annual)$0.11

ROA (5Y Avg)-18.85%

Net Profit Margin (Annual)6.35%

Month-to-Date Return30.09%

Cash Flow / Share (TTM)$-0.14

EBITD / Share (Annual)$0.12

Operating Margin (Annual)6.10%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)24.35x

ROI (5Y Avg)-34.10%

P/E Excl Extra (TTM)64.38x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.07

P/TBV (Quarterly)3.10x

P/B Ratio (Annual)5.08x

Inventory Turnover (TTM)2.75x

Pretax Margin (TTM)4.12%

Book Value / Share (Annual)$0.96

Price vs S&P 500 (13W)16.72%

Beta1.62x

P/FCF (Annual)30.37x

Revenue / Share (TTM)$1.74

ROE (TTM)7.66%

52-Week Low$2.66

vGradeC

gGradeC

mGradeC

vgmGradeC

NEPH Earnings Surprise History

Q2 250.02est. -0.03

Q3 250.03est. -0.02

Q4 250.01est. 0.01

Q1 260.01est. 0.01

Q2 260.05est. 0.01

NEPH Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.00

Industry Peers — Surgical & Medical Instruments(140)

Symbol	Value Score	Growth Score	Momentum Score	Price
NEPHNephros Inc.	C	C	C	$4.22
SYKStryker Corporation	C	B	C	$330.59
MMM3M Company	C	D	B	$179.37
BSXBoston Scientific Corp.	C	B	D	$49.86
BDXBecton, Dickinson and Co.	B	D	B	$189.78
MDLNMedline Inc. Class A common stock	C	D	C	$35.64
RMDResMed Inc.	C	B	C	$236.59
DXCMDexCom, Inc.	D	B	B	$89.16
WSTWest Pharmaceutical Services, Inc.	D	C	B	$348.48
SOLVSolventum Corporation	C	C	B	$91.61
BAXBaxter International Inc.	B	D	B	$26.29
PENPenumbra, Inc.	D	C	C	$324.37
GMEDGLOBUS MEDICAL INC	B	B	C	$82.96
GKOSGlaukos Corporation	F	A	A	$181.39
PODDInsulet Corporation	C	A	D	$143.05
STVNStevanato Group S.p.A.	D	C	B	$22.70
TFXTeleflex Incorporated	B	F	B	$140.18
MMSIMerit Medical Systems Inc	C	B	B	$91.09
MMEDMiniMed Group, Inc. Common Stock	—	—	A	$18.92
HAEHaemonetics Corporation	C	C	A	$108.32
ICUIICU Medical Inc	C	D	B	$182.24
HTFLHeartflow, Inc. Common Stock	—	A	A	$49.89
IRTCiRhythm Holdings, Inc. Common Stock	F	A	C	$123.09
PLSEPulse Biosciences, Inc Common Stock (DE)	F	—	A	$49.00
ATRCAtriCure, Inc.	D	B	A	$48.68
UFPTUFP Technologies Inc	C	B	B	$304.21
NVCRNovoCure Limited Ordinary Shares	D	C	C	$17.62
LMATLeMaitre Vascular, Inc.	C	B	D	$78.97
INSPInspire Medical Systems, Inc.	B	B	B	$61.07
KMTSKestra Medical Technologies, Ltd. Common Stock	F	A	B	$26.92
TNDMTandem Diabetes Care, Inc.	D	C	B	$21.58
ATECAlphatec Holdings, Inc.	D	B	C	$9.33
DRTSAlpha Tau Medical Ltd. Ordinary Shares	—	—	A	$14.70
IARTIntegra LifeSciences Holdings	B	D	C	$16.79
AORTArtivion, Inc.	C	C	C	$26.38
PRCTPROCEPT BioRobotics Corporation Common Stock	C	A	D	$21.60
IRMDiRadimed Corporation	D	B	C	$87.87
BVSBioventus Inc. Class A Common Stock	B	C	A	$14.08
SGPSpyGlass Pharma, Inc. Common Stock	—	—	B	$26.60
SIBNSI-BONE, Inc. Common Stock	D	B	B	$19.54
BBNXBeta Bionics, Inc. Common Stock	D	A	A	$19.34
SSIISS Innovations International Inc. Common Stock	F	A	D	$3.55
ANGOAngioDynamics, Inc.	C	D	B	$15.95
KIDSOrthoPediatrics Corp. Common Stock	C	B	B	$24.50
MDXGMiMedx Group, Inc	C	D	C	$4.34
DCTHDelcath Systems Inc	D	B	A	$16.92
BWAYBrainsway Ltd. American Depositary Shares	F	A	C	$14.43
CERSCerus Corp	D	C	B	$2.72
TCMDTactile Systems Technology, Inc.	B	B	C	$23.58
CLPTClearPoint Neuro, Inc. Common Stock	F	A	B	$16.96
NPCENeuropace, Inc. Common Stock	D	C	C	$14.16

About Nephros Inc.

Nephros Inc is a commercial-stage company developing high-performance water solutions for medical and commercial markets. The medical segment focuses on water filtration, pathogen detection, and next-generation hemodiafiltration systems for renal disease patients, while the commercial segment manufactures water filters that improve taste and reduce odor, biofilm, and equipment fouling. Revenue is primarily generated through product sales.